These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 32895455)

  • 1. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
    Dimopoulos M; Weisel K; Moreau P; Anderson LD; White D; San-Miguel J; Sonneveld P; Engelhardt M; Jenner M; Corso A; Dürig J; Pavic M; Salomo M; Casal E; Srinivasan S; Yu X; Nguyen TV; Biyukov T; Peluso T; Richardson P
    Leukemia; 2021 Jun; 35(6):1722-1731. PubMed ID: 32895455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.
    Sunami K; Matsue K; Suzuki K; Takezako N; Shinagawa A; Sakurai S; Tamakoshi H; Biyukov T; Peluso T; Richardson P
    Cancer Sci; 2020 Jun; 111(6):2116-2122. PubMed ID: 32297407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
    Richardson PG; Schjesvold F; Weisel K; Moreau P; Anderson LD; White D; Rodriguez-Otero P; Sonneveld P; Engelhardt M; Jenner M; Corso A; Dürig J; Pavic M; Salomo M; Beksac M; Oriol A; Lindsay J; Liberati AM; Galli M; Robak P; Larocca A; Yagci M; Vural F; Kanate AS; Jiang R; Grote L; Peluso T; Dimopoulos M
    Eur J Haematol; 2022 Jan; 108(1):73-83. PubMed ID: 34496096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
    Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
    Oriol A; Dimopoulos M; Schjesvold F; Beksac M; Facon T; Dhanasiri S; Guo S; Mu Y; Hong K; Gentili C; Galli M; Yagci M; Larocca A; Richardson P; Weisel K
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):165-176.e4. PubMed ID: 38072743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
    Dimopoulos MA; Beksac M; Pour L; Delimpasi S; Vorobyev V; Quach H; Spicka I; Radocha J; Robak P; Kim K; Cavo M; Suzuki K; Morris K; Pompilus F; Phillips-Jones A; Zhou XL; Fulci G; Sule N; Kremer BE; Opalinska J; Mateos MV; Trudel S;
    N Engl J Med; 2024 Aug; 391(5):408-421. PubMed ID: 38828951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
    Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
    Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
    Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
    Bahlis NJ; Dimopoulos MA; White DJ; Benboubker L; Cook G; Leiba M; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Krevvata M; Chiu C; Qin X; Okonkwo L; Trivedi S; Ukropec J; Qi M; San-Miguel J
    Leukemia; 2020 Jul; 34(7):1875-1884. PubMed ID: 32001798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
    Mohty M; Terpos E; Mateos MV; Cavo M; Lejniece S; Beksac M; Bekadja MA; Legiec W; Dimopoulos M; Stankovic S; Durán MS; De Stefano V; Corso A; Kochkareva Y; Laane E; Berthou C; Salwender H; Masliak Z; Pečeliūnas V; Willenbacher W; Silva J; Louw V; Nemet D; Borbényi Z; Abadi U; Pedersen RS; Černelč P; Potamianou A; Couturier C; Feys C; Thoret-Bauchet F; Boccadoro M;
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e401-e419. PubMed ID: 30030033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
    Chng WJ; Goldschmidt H; Dimopoulos MA; Moreau P; Joshua D; Palumbo A; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Feng S; Aggarwal S; Hájek R
    Leukemia; 2017 Jun; 31(6):1368-1374. PubMed ID: 28025582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
    Siegel DS; Schiller GJ; Song KW; Agajanian R; Stockerl-Goldstein K; Kaya H; Sebag M; Samaras C; Malek E; Talamo G; Seet CS; Mouro J; Pierceall WE; Zafar F; Chung W; Srinivasan S; Agarwal A; Bahlis NJ
    Br J Haematol; 2020 Feb; 188(4):501-510. PubMed ID: 31588567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
    Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
    Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma.
    Weisel K; Dimopoulos M; Moreau P; Yagci M; Larocca A; Kanate AS; Vural F; Cascavilla N; Basu S; Johnson P; Byeff P; Hus M; Rodríguez-Otero P; Muelduer E; Anttila P; Hayden PJ; Krauth MT; Lucio P; Ben-Yehuda D; Mendeleeva L; Guo S; Yu X; Grote L; Biyukov T; Dhanasiri S; Richardson P
    Leuk Lymphoma; 2020 Aug; 61(8):1850-1859. PubMed ID: 32268815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
    Moreau P; Joshua D; Chng WJ; Palumbo A; Goldschmidt H; Hájek R; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Aggarwal S; Feng S; Dimopoulos MA
    Leukemia; 2017 Jan; 31(1):115-122. PubMed ID: 27491641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
    Jacobus SJ; Rajkumar SV; Weiss M; Stewart AK; Stadtmauer EA; Callander NS; Dreosti LM; Lacy MQ; Fonseca R
    Blood Cancer J; 2016 Jul; 6(7):e448. PubMed ID: 27471864
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
    Oka S; Ono K; Nohgawa M
    J Clin Pharm Ther; 2018 Dec; 43(6):914-917. PubMed ID: 29974481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.